-
Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements
•
Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms Zhejiang International Group Co., Ltd. and Jianmin International Co., Ltd. These collaborations aim to enhance Teva’s commercial layout in the “One Health” sector, increasing the availability of quality products for Chinese consumers. Strategic Agreements at…
-
Teva Pharmaceutical Reports Positive Phase III Results for TEV-‘749 in Schizophrenia Trial
•
Israel-based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has released new positive data on social functioning and quality of life from the Phase III Subcutaneous Olanzapine Extended-Release Injection Study (SOLARIS) trial. The study assesses the efficacy of TEV-‘749 in adult patients diagnosed with schizophrenia. SOLARIS Study Design and TEV-‘749’s EfficacyThe SOLARIS…
-
Teva Pharmaceutical Reaches Settlement with DOJ Over Alleged Kickbacks and Price-Fixing
•
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has entered into a settlement agreement with the U.S. Department of Justice (DOJ) to resolve allegations of misconduct related to its multiple sclerosis (MS) therapy, Copaxone. The DOJ had filed a lawsuit in August 2020, accusing Teva of violating the Anti-Kickback…
-
Teva’s Ajovy Achieves Positive Results in Phase III Migraine Prevention Trial in China
•
Teva Pharmaceutical Industries Ltd (NYSE: TEVA), headquartered in Israel, has announced positive results from a Phase III study for Ajovy (fremanezumab) as a preventive treatment for migraine in adult Chinese patients. The study met its primary and all secondary endpoints, demonstrating Ajovy’s efficacy in reducing the number of migraine days…
-
Alvotech Scores FDA Nod for Interchangeable High-Concentration Biosimilar to Humira
•
The US Food and Drug Administration (FDA) has granted approval to Iceland-based Alvotech’s (NASDAQ: ALVO) Simlandi, marking it as the first interchangeable high-concentration, citrate-free biosimilar to AbbVie’s (NYSE: ABBV) immunosuppressant Humira (adalimumab). Humira faced patent expiration in the US last year, leading to biosimilar competition. Simlandi is approved for various…
-
Teva Pharmaceuticals Initiates Spin-off of TAPI Unit, Targeting 2025 for Completion
•
Teva Pharmaceutical Industries Ltd., (NYSE: TEVA) a transnational generic drugs giant with Israeli and U.S. origins, has confirmed speculation in the market by announcing its intention to spin off its Active Pharmaceutical Ingredient (API) division, TAPI. This strategic move is part of Teva’s ‘pivot to growth’ initiative, aiming to streamline…
-
Chiesi Farmaceutici and Shanghai Pharmaceutical Partner on Distribution at CIIE
•
Among the series of deals secured by multinational corporations at the 6th China International Import Expo (CIIE), Italy-based Chiesi Farmaceutici S.p.A. has inked a partnership with Shanghai Pharmaceuticals Co., Ltd (SHA: 601607, HKG: 2607). This strategic alliance aims to capitalize on Shanghai Pharmaceutical’s extensive distribution network. As reported by Shine,…
-
Teva Partners with CR Guangdong to Launch Fremanezumab for Migraines in China’s GBA
•
Israel-based generics specialist Teva (NYSE: TEVA) has announced the initiation of a strategic partnership with China-headquartered China Resources Guangdong Pharmaceutical Co., Ltd (CR Guangdong). This collaboration aims to leverage CR Guangdong’s logistics and supply chain management expertise to support the introduction of Teva’s migraine therapy, fremanezumab, in the Greater Bay…
